clinical trial · NCT05161936
A Study to Evaluate Lumasiran in Adults With Recurrent Calcium Oxalate Kidney Stone Disease and Elevated Urinary Oxalate Levels
Recurrent Calcium Oxalate Kidney Stone DiseaseElevated Urinary Oxalate LevelsLumasiranPlacebo
brief summary
The primary purpose of this study is to evaluate the effect of lumasiran on the percent change in urinary oxalate excretion in patients with recurrent calcium oxalate kidney stone disease.
started
Jan 27, 2022
primary completion
Nov 1, 2022
completion
Nov 1, 2022
last updated
May 22, 2024
official title
A Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy, Safety, Pharmacodynamics, and Pharmacokinetics of Lumasiran in Patients With Recurrent Calcium Oxalate Kidney Stone Disease and Elevated Urinary Oxalate Levels
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol